The product information states that the premedication for obinutuzumab should consist of an analgesic/antipyretic, an antihistamine and an intravenous corticosteroid for the first initial dose.
For subsequent infusions:
- Antihistamine premedication may be omitted for subsequent infusions if no infusion related reactions (IRR) occurred with the previous infusion.
- Intravenous corticosteroid* premedication may be omitted for subsequent infusions if no grade 1 or 2 infusion related reactions (IRR) occurred with the previous infusion. If a grade 3 IRR occurred OR lymphocyte counts > 25 x109/L prior to next treatment, intravenous corticosteroid premedication should be continued.
- Analgesic/antipyretic premedication is given before all infusions.
A suggested default premedication has been added to the treatment schedule, and may be substituted to reflect institutional policy.
Note: hydrocortisone is not recommended as it has not been effective in reducing the rate of infusion reactions.
* IV corticosteroid (may be substituted by oral corticosteroids if contained within the chemotherapy regimen)